Loading...
Market
Which regulatory authority will first approve a drug from Insitro-Eli Lilly collaboration by 2028?
3
Resolution / Starting Odds
FDA (USA) • 25%
EMA (Europe) • 25%
PMDA (Japan) • 25%
Other • 25%
Regulatory authority announcements or press releases from Insitro or Eli Lilly
Story
Insitro and Eli Lilly Announce AI Deal to Accelerate Genetic Medicine Development
Oct 9, 2024, 03:30 PM
Insitro has announced a collaboration with Eli Lilly and Company to accelerate the development of Insitro's genetic medicine using Lilly's proprietary GalNAc delivery technology and expertise in biologics design. The partnership aims to bring Insitro's discoveries to the clinic, with the first drug expected to enter clinical trials by 2026. Insitro retains full global rights to its discoveries, while Lilly is eligible to receive potential benefits from the collaboration. The collaboration also includes an AI deal between Insitro and Eli Lilly.
View original story
Similar markets
FDA (USA) • 25%
EMA (EU) • 25%
MHRA (UK) • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Insilico Medicine • 25%
Amgen • 25%
Terray Therapeutics • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Before June 30, 2025 • 25%
Between July 1, 2025 and December 31, 2025 • 25%
After December 31, 2025 • 25%
No drug approval by December 31, 2025 • 25%